Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study

Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and a star medication used to treat non-small-cell lung carcinomas (NSCLCs). It has caused broad public concern that osimertinib has relatively low stability in plasma. We explored why osimertinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Zheng, Yu, Xin, Wu, Siyang, Wu, Xiaonan, Wang, Qiutao, Cheng, Wenhao, Hu, Weiyu, Kang, Chen, Yang, Wei, Li, Yingfei, Zhou, Xiao-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354582/
https://www.ncbi.nlm.nih.gov/pubmed/35935836
http://dx.doi.org/10.3389/fphar.2022.928983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354582/
https://www.ncbi.nlm.nih.gov/pubmed/35935836
http://dx.doi.org/10.3389/fphar.2022.928983

Ejemplares similares